Wall Street analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings of ($1.19) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($1.13) and the lowest is ($1.30). Global Blood Therapeutics posted earnings of ($0.93) per share in the same quarter last year, which would suggest a negative year over year growth rate of 28%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 26th.
On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.27) to ($4.09). For the next fiscal year, analysts forecast that the company will report earnings of ($4.61) per share, with EPS estimates ranging from ($5.57) to ($4.02). Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the company earned ($0.83) EPS.
GBT has been the topic of a number of research reports. Janney Montgomery Scott raised their price objective on Global Blood Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Cowen set a $83.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 9th. Piper Jaffray Companies boosted their target price on Global Blood Therapeutics from $80.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Global Blood Therapeutics in a research note on Thursday, September 5th. Finally, Wedbush restated a “buy” rating and set a $143.00 price objective on shares of Global Blood Therapeutics in a research note on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $91.44.
In other Global Blood Therapeutics news, insider Joshua Lehrer-Graiwer sold 11,593 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $67.19, for a total transaction of $778,933.67. Following the completion of the sale, the insider now directly owns 312 shares in the company, valued at approximately $20,963.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider De Dominicis Robert 490,012 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. In the last ninety days, insiders have sold 36,616 shares of company stock valued at $2,096,540. 4.30% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Quest Capital Management Inc. ADV purchased a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $26,000. Steward Partners Investment Advisory LLC acquired a new stake in Global Blood Therapeutics in the second quarter valued at $27,000. Lindbrook Capital LLC boosted its position in shares of Global Blood Therapeutics by 133.3% during the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock worth $34,000 after purchasing an additional 400 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth $42,000. Finally, Truvestments Capital LLC grew its stake in shares of Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock worth $45,000 after purchasing an additional 300 shares during the period. 98.78% of the stock is currently owned by institutional investors and hedge funds.
Global Blood Therapeutics stock traded up $0.44 during mid-day trading on Wednesday, reaching $72.93. The company’s stock had a trading volume of 68,652 shares, compared to its average volume of 1,331,700. The firm’s fifty day moving average price is $53.03 and its two-hundred day moving average price is $53.44. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.95 and a current ratio of 14.95. Global Blood Therapeutics has a 12-month low of $34.92 and a 12-month high of $73.23. The company has a market capitalization of $4.01 billion, a P/E ratio of -21.39 and a beta of 1.70.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Further Reading: How is a price target determined?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.